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Cost Effectiveness of Mohs
Micrographic Surgery
Robert S. Stern1
Chren’s study provides further evidence that for primary facial nonmelanoma skin
cancers (NMSCs), recurrence rates with Mohs micrographic surgery (MMS) are
modestly better than those for excision surgery. In 20 years, use of MMS has
grown B10-fold and its cost now exceeds two billion dollars annually. Clinical
experience and available data suggest that the skill of the treating physician is
at least as important a determinant of outcome as the choice of MMS or excision.
As patients and referring physicians increasingly share in the cost of more
expensive procedures, evidence-based guidelines that establish the clinical
circumstances in which the additional benefits of MMS outweigh its higher cost
are needed, still lacking, and unlikely to become available.
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Over the years, I have worked with a
number of highly skilled Mohs surgeons
who provide excellent care to our
patients. Mohs units are one of the
financial underpinnings of many depart-
ments of dermatology. The growth of
Mohs micrographic surgery (MMS) over
the past 35 years has been extraordin-
ary. In 1976, I did not know anyone in
the greater Boston area who was a full-
time Mohs surgeon. Now, the Mohs
College lists more than two dozen to
whom I could bicycle to in less than half
an hour. This excludes an unknown, but
not insubstantial, number of individuals
who are not members of the Mohs
College, but provide what they call
MMS. MMS fellowships attracts many
of our brightest residents.
For recurrent nonmelanoma skin can-
cers (NMSCs) in the ‘‘H zone’’, MMS is
clearly superior to excision, and in most
cases is the treatment of choice (Smeets
et al., 2004; Mosterd et al., 2008).
However, recurrent tumors represent
only a minority of all tumors treated
with MMS in the United States. For
primary NMSCs even in the H zone,
the new study of Chren et al. (2013, this
issue) as well as the Dutch study
showed little difference between MMS
and excision (Smeets et al., 2004;
Mosterd et al., 2008). The use of MMS
may provide greater standardization and
hence less variance in recurrence rates
among providers than does excision. On
the other hand, the study of Chren et al.
(2012) suggests that the results among
surgeons performing excisions may vary
substantially. More predictability in the
risk of recurrence may be beneficial to
the individual patient with tumors at
sites such as the ‘‘H zone’’ where
recurrence is likely to result in substan-
tial morbidity, but the data available
argue more strongly for using a skilled
physician than choosing an MMS over
excision for primary NMSC.
Medicare data document the excep-
tional growth in the utilization of MMS.
From 1992 to 2002, the utilization of
MMS increased 332% (Maxwell et al.,
2007). By 2009, the rate of the use of
MMS was 700% greater than in 1992
(Donaldson and Coldiron, 2012). Extra-
polated to 2013, nearly 2% of all Medi-
care recipients will have MMS in that
year. Is that too many or not enough?
When more robust data are not avail-
able, one approach to assessing the
appropriateness of the utilization of a
procedure in various populations is
‘‘small area variation’’ (Wennberg and
Gittelsohn, 1973). This technique
assumes that if the rates of utilization
vary greatly among areas, factors other
than medical appropriateness are likely
to be playing a role in the use of that
treatment. The high variability in the
utilization of MMS as measured by the
percentage of all NMSC procedures
by state provides evidence that the
utilization of MMS is highly unlikely to
reflect the application of uniform
clinical criteria. Recent Medicare data
emphasize differences in the utilization
of MMS (Donaldson and Coldiron,
2012). In New Mexico, 12% of
NMSCs of the face, scalp, neck, hands,
feet, and genitalia are treated with
MMS. In Minnesota, MMS is used in
53% of such tumors. It is hard to
imagine the clinical differences in
these populations that would explain
this difference. For NMSCs located on
the trunk, arms, and legs, the proportion
of tumors treated with MMS varied
among states by more than 15-fold (yes
by 1,500%). Not surprisingly, states with
a higher proportion of tumors on face,
neck, hands, feet, and genitalia had
a higher proportion of MMS-treated
tumors at other sites (Po0.0001)
Figure 1.
In 2009, B1,800 providers billed
Medicare for MMS (Donaldson and
Coldiron, 2012). Nearly half of these
providers did o200 cases for Medicare
beneficiaries. More than half of the
MMS patients are likely to be
Medicare beneficiaries (Smeets et al.,
2004; Stern, 2010; Chren et al., 2013).
Low-volume providers are less likely to
provide efficient and optimal service.
By contrast, slightly more than 10%
of providers of MMS to Medicare
beneficiaries accounted for nearly 40%
of all Mohs procedures.
This year, MMS is likely to cost more
than two billion dollars in the United
States. In addition to recurrent tumors,
on clinical grounds but without robust
comparative clinical efficacy data to
support these ‘‘impressions,’’ one
expects Mohs to be superior to excision
for large tumors, those with aggressive
histology, or indistinct borders in critical
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areas. The best comparative clinical
effectiveness data suggest that for many
and probably most NMSCs treated with
Mohs in the United States today, exci-
sion would be equally efficacious with
results measured by recurrence rates
(Smeets et al., 2004; Mosterd et al.,
2008; Chren et al., 2013).
A large multisurgeon randomized trial
would definitely provide a more robust
estimate of the relative effectiveness and
variability among surgeons for MMS and
excision and which primary NMSCs
more likely benefit from Mohs.
Although needed, I doubt that such a
study is likely to be conducted.
The earlier work of Chren et al. (2007)
suggests that quality-of-life improve-
ments following treatment of NMSC do
not differ between MMS and excision.
The Dutch group assessed preferences
between excision and MMS in the
general public based on a discrete
choice experiment using hypothetical
scenarios (Essers et al., 2010). Their
conclusion was that the general public
preferred MMS. However, this result
may have reflected a higher probability
of the recurrence after excision than
what the group of Chren or their group
found in their studies (Mosterd, 2008;
Chren et al., 2013). The Dutch group
found that the cosmetic results of
excision and MMS were similar (Essers
et al., 2007).
A number of publications claim that
MMS is no more expensive than surgical
excision of primary NMSCs, but these
claims do not pass the test of face vali-
dity or a quick look at reimbursement
schedules. The Dutch group studied the
resource utilization that is required for
MMS and surgical excision of basal cell
carcinoma of the face. On the basis of
resource utilization, MMS requires more
resources than excision (Essers et al.,
2006). On the basis of aggregate claims
data, Mohs treatment is about twice as
expensive as surgical excision of NMSC
(Wilson et al., 2012). With the high
proportion of all NMSCs treated with
MMS, it is hard to argue that these cost
differences are explained solely by
greater complexity of Mohs-treated cases.
Previously, for most patients, the out-
of-pocket costs of MMS and excision
have been equal. Increasingly, however,
patients are sharing in the cost of the
medical care they receive and paying
more for more expensive procedures.
With changes in reimbursement that
include global payment and capitation,
primary-care providers and dermatolo-
gists who diagnose NMSCs, but do not
provide MMS, may be at financial risk
when they choose to refer a patient for a
higher-cost procedure such as the MMS.
At the same time, the number of persons
offering MMS continues to expand. How
these trends will impact the use of and
reimbursement for MMS is uncertain.
Both the MMS community and the
American Academy of Dermatology
have recently published ‘‘Appropriate
Use Criteria’’ for MMS (Connolly et al.,
2012). In only 17% of 270 scenarios
evaluated was MMS considered inap-
propriate. These ‘‘inappropriate’’ scen-
arios for the use of MMS largely conce-
rned small tumors of the trunk and
extremities or ‘‘actinic keratosis, with
focal SCC in situ.’’ Given the variabili-
ties in the clinical presentation of NMSC
and patients’ preferences, difficulties of
physicians, insurers, and patients in
setting clear criteria are not surprising.
For recurrent and probably high-risk
primary NMSCs (but what characterize
high risk is still unclear), MMS is
advantageous (Smeets et al., 2004;
Mosterd, 2008). However, the available
data suggest that many and perhaps
most MMS-treated NMSCs in the
United States are not high-risk tumors.
For these tumors, the decision to utilize
MMS is likely to reflect the economic
advantage to the provider rather than a
substantial clinical advantage for the
patient. Unfortunately, reimbursement
policies that remove the financial
motivations to perform MMS but fail
to provide adequate reimbursement for
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Figure 1. Percent of all nonmelanoma skin cancers treated with Mohs micrographic surgery (MMS)
(2009) by state and body site. x Axis: face, scalp, hands, feet, and genitalia (face and other sites).
y Axis: trunk, arms, and legs (trunk and extremities). Each data point represents results for a state. The line
shows the relationship between the percentage of patients treated with MMS on face, scalp, hands, feet,
and genitalia versus other body sites (least squares plot). Data points for selected states are identified by
color. The number of Mohs College members per million white population is provided in parenthesis
(utilization data from Donaldson and Coldiron (2012). Yellow: New Mexico (2.9); red: Arkansas (3.2);
purple: New York (6.6); blue: Nevada (2.8).
Clinical Implications
 The study of Chren et al. (2013) adds to data from a European comparative
effectiveness study that indicates that the outcome of Mohs micrographic
surgery (MMS) is at most slightly superior to that of the excision for
primary facial nonmelanoma skin cancer.
 A large multisurgeon randomized trial would provide a robust estimate of
the relative effectiveness and variability among surgeons for MMS and
excision for primary nonmelanoma skin cancers.
 Although needed, such a study is unlikely to be done.
 In the United States, the use of Mohs for Medicare beneficiaries increased
700% between 1992 and 2009.
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MMS of recurrent and high-risk NMSCs
are most likely to impact the Mohs units
that provide services to those most in
need of this valuable but overused
procedure.
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‘‘Patch’’ing Up Our Tumor Signaling
Knowledge
Scott X. Atwood1,2, Ramon J. Whitson1,2 and Anthony E. Oro1
The tumor suppressor Patched1 (Ptch1) possesses well-described roles in
regulating sonic hedgehog (SHH) signaling in the skin and preventing the
formation of basal cell carcinomas (BCCs). In this issue, Kang et al. extend their
previous work to show that a naturally occurring allele of Ptch1 found in FVB mice
promotes early squamous cell carcinoma (SCC) growth without aberrant activa-
tion of the SHH pathway. The study reveals new roles for Ptch1 that lie at the
nexus between BCC and SCC formation.
Journal of Investigative Dermatology (2013) 133, 1131–1133. doi:10.1038/jid.2012.506
The sonic hedgehog (SHH) signaling
pathway has key roles during embryonic
development, cell fate decisions, and
tumor formation (Hui and Angers,
2011; Ingham et al., 2011). SHH binds
to its receptor Patched1 (Ptch1),
releasing Smoothened (Smo) inhibition
that results in Gli-dependent transcrip-
tion of SHH target genes. Inactivating
mutations in Ptch1 in the skin promotes
formation of basal cell carcinomas (BCCs)
at high frequency and are the cause of
Gorlin syndrome in the germline (Hahn
et al., 1996). Although Gorlin patients
have well-characterized susceptibility
to other SHH-dependent tumors, Ptch1
loss in these patients does not appear to
contribute to excessive SCC develop-
ment. Moreover, sporadic BCCs also rely
on high levels of SHH target gene indu-
ction for tumor growth, providing the
rational for development of a targeted
therapy. Indeed, inhibition of the SHH
pathway with Smo antagonists recently
received Food and Drug Administration
approval for the treatment of late
advanced or metastatic BCCs, and they
have shown impressive efficacy in
Gorlin patients (Atwood et al., 2012).
Although the role for Ptch1 in BCC
tumor suppression is clear, surprisingly
little is known about how this enigmatic
protein functions at a mechanistic level.
Ptch1 is a member of the sterol-sensing
domain family and shares identity
with the ABC transporter family (Ingham
et al., 2011). Although this suggests it
pumps key signaling molecules, none so
far has been identified unequivocably.
Moreover, Ptch1 function in suppressing
Smo, arguably its most oft-written role,
has not been delineated. Although it is
clear that SHH binding to Ptch1 acti-
vates Smo, how the two proteins interact
remains unknown. Initial studies sug-
gested that the two proteins form a
complex and argued for direct allosteric
inhibition (Carpenter et al., 1998;
Murone et al., 1999). However, later
quantitative studies indicated that Ptch1
acts catalytically, suggesting it controls an
enzymatic modifier of Smo function
(Ingham et al., 2000; Taipale et al.,
2002). Recently, entry into the primary
cilium, a microtubule based organelle,
has been shown to be important for Smo
function, and Ptch1 appears to regulate
ciliary entry in an as yet unknown
manner (Rohatgi et al., 2007).
Ptch1FVB promotes Ras-induced skin
tumorigenesis
Distinct from its role in controlling the
SHH pathway, recent studies indicate a
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